메뉴 건너뛰기




Volumn 7, Issue 5, 2007, Pages 463-470

Botulinum toxin type A in chronic migraine

Author keywords

Botulinum toxin type A; Chronic migraine; Medication overuse

Indexed keywords

ANALGESIC AGENT; BOTULINUM TOXIN A; OPIATE; PLACEBO;

EID: 34248372532     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.5.463     Document Type: Review
Times cited : (9)

References (43)
  • 1
    • 0028132976 scopus 로고
    • Tension type headache: Botulinum toxin paralysis of temporal muscles
    • Zwart JA, Bovim G, Sand T, Sjaastad O. Tension type headache: botulinum toxin paralysis of temporal muscles. Headache 34, 458-462 (1994).
    • (1994) Headache , vol.34 , pp. 458-462
    • Zwart, J.A.1    Bovim, G.2    Sand, T.3    Sjaastad, O.4
  • 2
    • 0000019463 scopus 로고
    • Resolution of chronic tension type headache after botulinum toxin treatment of idiopathic blepharospasm
    • Krack P, Hornig C, Dorndorf W. Resolution of chronic tension type headache after botulinum toxin treatment of idiopathic blepharospasm. Mov. Disord. 10, 388 (1995).
    • (1995) Mov. Disord , vol.10 , pp. 388
    • Krack, P.1    Hornig, C.2    Dorndorf, W.3
  • 3
    • 0033668492 scopus 로고    scopus 로고
    • Botulinum toxin type A (BOTOX) for the treatment of migraine headaches: An open label study
    • Binder WJ, Brin MF, Blitzer A, Schoenrock LD. Botulinum toxin type A (BOTOX) for the treatment of migraine headaches: an open label study. Otolaryngol. Head Neck Surg. 123, 669-676 (2000).
    • (2000) Otolaryngol. Head Neck Surg , vol.123 , pp. 669-676
    • Binder, W.J.1    Brin, M.F.2    Blitzer, A.3    Schoenrock, L.D.4
  • 4
    • 33748271738 scopus 로고    scopus 로고
    • Botulinum toxin: Chemistry, pharmacology, toxicity and immunology
    • Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity and immunology. Muscle Nerve (Suppl. 6), S146-S168 (1997).
    • (1997) Muscle Nerve , Issue.SUPPL. 6
    • Brin, M.F.1
  • 5
    • 33645099746 scopus 로고    scopus 로고
    • Pharmacology of botulinum toxin: Differences between type A preparations
    • Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur. J. Neurol. 13(Suppl. 1), 2-10 (2006).
    • (2006) Eur. J. Neurol , vol.13 , Issue.SUPPL. 1 , pp. 2-10
    • Rosales, R.L.1    Bigalke, H.2    Dressler, D.3
  • 6
    • 0029920995 scopus 로고    scopus 로고
    • Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection
    • Rosales RI, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve 19, 488-496 (1996).
    • (1996) Muscle Nerve , vol.19 , pp. 488-496
    • Rosales, R.I.1    Arimura, K.2    Takenaga, S.3    Osame, M.4
  • 8
    • 0017701735 scopus 로고
    • The action of botulinum a neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex
    • Wiegand H, Wellhoner HH. The action of botulinum a neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch. Pharmacol. 298, 235-238 (1977).
    • (1977) Naunyn Schmiedebergs Arch. Pharmacol , vol.298 , pp. 235-238
    • Wiegand, H.1    Wellhoner, H.H.2
  • 9
    • 0017315001 scopus 로고
    • I125-labeled botulinum A neurotoxin: Pharmacokinetics in cats after intramuscular injection
    • Wiegand H, Erdmann G, Wellhoner HH. I125-labeled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch. Pharmacol. 292, 161-165 (1976).
    • (1976) Naunyn Schmiedebergs Arch. Pharmacol , vol.292 , pp. 161-165
    • Wiegand, H.1    Erdmann, G.2    Wellhoner, H.H.3
  • 10
    • 0031731126 scopus 로고    scopus 로고
    • The development of BOTOX - its history and pharmacology
    • Aoki R. The development of BOTOX - its history and pharmacology. Pain Digest 8, 337-341 (1998).
    • (1998) Pain Digest , vol.8 , pp. 337-341
    • Aoki, R.1
  • 11
    • 0034603438 scopus 로고    scopus 로고
    • Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles
    • Iskawa H, Mitsui Y, Yoshitomi T. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J. Opthalmol. 44, 106-109 (2000).
    • (2000) Jpn J. Opthalmol , vol.44 , pp. 106-109
    • Iskawa, H.1    Mitsui, Y.2    Yoshitomi, T.3
  • 12
    • 0030024791 scopus 로고    scopus 로고
    • Effect of muscle denervation on the expression of substance P in the ventral raphe-spinal pathway of the rat
    • Van den Bergh P, De Beukelaer M, Deconinek N. Effect of muscle denervation on the expression of substance P in the ventral raphe-spinal pathway of the rat. Brain Res. 707, 206-212 (1996).
    • (1996) Brain Res , vol.707 , pp. 206-212
    • Van den Bergh, P.1    De Beukelaer, M.2    Deconinek, N.3
  • 13
    • 0034053450 scopus 로고    scopus 로고
    • Enkephalin and aFGF are differentially regulated in the rat spinal motor neurons after chemodenervation with botulinum toxin
    • Humm Am, Pabst C, Lauterberg T, Burgunder JM. Enkephalin and aFGF are differentially regulated in the rat spinal motor neurons after chemodenervation with botulinum toxin. Exp. Neurol. 161, 361-372 (2000).
    • (2000) Exp. Neurol , vol.161 , pp. 361-372
    • Humm, A.1    Pabst, C.2    Lauterberg, T.3    Burgunder, J.M.4
  • 14
    • 0000099458 scopus 로고    scopus 로고
    • Botulinum toxin type A reduces inflammatory pain the rat formalin model
    • Cui M, Aoki KR. Botulinum toxin type A reduces inflammatory pain the rat formalin model. Cephalalgia 20, 414 (2000).
    • (2000) Cephalalgia , vol.20 , pp. 414
    • Cui, M.1    Aoki, K.R.2
  • 15
    • 26444469528 scopus 로고    scopus 로고
    • Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A
    • Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26, 785-793 (2005).
    • (2005) Neurotoxicology , vol.26 , pp. 785-793
    • Aoki, K.R.1
  • 16
    • 33745778274 scopus 로고    scopus 로고
    • The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain
    • Park HJ, Lee Y, Lee J, Park C, Moon DE. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can. J. Anaesth. 53, 470-477 (2006).
    • (2006) Can. J. Anaesth , vol.53 , pp. 470-477
    • Park, H.J.1    Lee, Y.2    Lee, J.3    Park, C.4    Moon, D.E.5
  • 17
    • 33745000127 scopus 로고    scopus 로고
    • The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization
    • Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122, 315-325 (2006).
    • (2006) Pain , vol.122 , pp. 315-325
    • Gazerani, P.1    Staahl, C.2    Drewes, A.M.3    Arendt-Nielsen, L.4
  • 18
    • 33745058028 scopus 로고    scopus 로고
    • Kim DY, Oh BM, Paik NJ. Central effect of botulinum toxin type A in humans. Int. J. Neurosci. 116, 667-680 (2006). • Although botulinum toxin type A has long been recognized for its effect on skeletal muscle, it proved a difficult concept to accept as a mechanism for the treatment of migraine headache. Further research presented a more rational explanation for the potential efficacy in migraine and related headache disorders.
    • Kim DY, Oh BM, Paik NJ. Central effect of botulinum toxin type A in humans. Int. J. Neurosci. 116, 667-680 (2006). • Although botulinum toxin type A has long been recognized for its effect on skeletal muscle, it proved a difficult concept to accept as a mechanism for the treatment of migraine headache. Further research presented a more rational explanation for the potential efficacy in migraine and related headache disorders.
  • 19
    • 33745184401 scopus 로고    scopus 로고
    • Headache Classification Committee: New appendix criteria open for a broader concept of chronic migraine
    • Olesen J, Bousser M-G, Diener H-C et al. Headache Classification Committee: new appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26, 742-746 (2006).
    • (2006) Cephalalgia , vol.26 , pp. 742-746
    • Olesen, J.1    Bousser, M.-G.2    Diener, H.-C.3
  • 20
    • 0142258184 scopus 로고    scopus 로고
    • Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106, 81-89 (2003). •• Why patients with a history of episodic migraine would evolve from periodic headaches to daily headaches was really a matter of conjecture and based on biases of clinicians. This large epidemiologic survey, which looked beyond factors strictly associated with a headache, such as frequency, severity, duration and use of treatments, opened a variety of avenues across disciplines to monitor for risk factors that could be addressed to alter disease evolution.
    • Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106, 81-89 (2003). •• Why patients with a history of episodic migraine would evolve from periodic headaches to daily headaches was really a matter of conjecture and based on biases of clinicians. This large epidemiologic survey, which looked beyond factors strictly associated with a headache, such as frequency, severity, duration and use of treatments, opened a variety of avenues across disciplines to monitor for risk factors that could be addressed to alter disease evolution.
  • 21
    • 33744790578 scopus 로고    scopus 로고
    • Frequency of headache is related to sensitization: A population study
    • Buchgreitz L, Lyngberg AC, Bendtsen L, Jensen R. Frequency of headache is related to sensitization: a population study. Pain 123, 19-27 (2006).
    • (2006) Pain , vol.123 , pp. 19-27
    • Buchgreitz, L.1    Lyngberg, A.C.2    Bendtsen, L.3    Jensen, R.4
  • 22
    • 27644459862 scopus 로고    scopus 로고
    • Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can Allodynic migraine patients be identified interictally using a questionnaire? Neurology 65, 1419-1422 (2005). •• Quantitative sensory testing had been demonstrated in the laboratory to have importance as a predictor of response to acute migraine medications. Its occurrence had been linked to disease duration and age of the patient as risk factors for its development, factors that were also apparent for chronicity in migraine. However, the methods are not readily applicable to the clinical setting. The use of a simple questionnaire allows practical assessment of this modulator of treatment response as well as making the occurrence of allodynia a practical teaching tool for patients.
    • Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can Allodynic migraine patients be identified interictally using a questionnaire? Neurology 65, 1419-1422 (2005). •• Quantitative sensory testing had been demonstrated in the laboratory to have importance as a predictor of response to acute migraine medications. Its occurrence had been linked to disease duration and age of the patient as risk factors for its development, factors that were also apparent for chronicity in migraine. However, the methods are not readily applicable to the clinical setting. The use of a simple questionnaire allows practical assessment of this modulator of treatment response as well as making the occurrence of allodynia a practical teaching tool for patients.
  • 23
    • 4644367464 scopus 로고    scopus 로고
    • Clinical recognition of allodynia in migraine
    • Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology 63, 848-852 (2004).
    • (2004) Neurology , vol.63 , pp. 848-852
    • Mathew, N.T.1    Kailasam, J.2    Seifert, T.3
  • 24
    • 22944445775 scopus 로고    scopus 로고
    • Freitag FG, Kozma CM, Slaton T, Osterhaus JT, Barron R .Characterization and prediction of emergency department use in chronic daily headache patients. Headache 45, 891-898 (2005). • The implications of chronic headache have far-reaching consequences beyond the state of health of the patient. The pharmacoeconomic consequences are issues that attract the attention of insurers and employers and may increase the potential treatment options for these patients.
    • Freitag FG, Kozma CM, Slaton T, Osterhaus JT, Barron R .Characterization and prediction of emergency department use in chronic daily headache patients. Headache 45, 891-898 (2005). • The implications of chronic headache have far-reaching consequences beyond the state of health of the patient. The pharmacoeconomic consequences are issues that attract the attention of insurers and employers and may increase the potential treatment options for these patients.
  • 25
    • 0036754971 scopus 로고    scopus 로고
    • Health resource utilization of the emergency department headache 'repeater'
    • Maizels M. Health resource utilization of the emergency department headache 'repeater'. Headache 42, 747-753 (2002).
    • (2002) Headache , vol.42 , pp. 747-753
    • Maizels, M.1
  • 26
    • 0942268948 scopus 로고    scopus 로고
    • Chronic migraineurs: An important subgroup of patients who visit emergency departments frequently
    • Chan BT, Ovens HJ. Chronic migraineurs: an important subgroup of patients who visit emergency departments frequently. Ann. Emerg. Med. 43, 238-242 (2004).
    • (2004) Ann. Emerg. Med , vol.43 , pp. 238-242
    • Chan, B.T.1    Ovens, H.J.2
  • 27
    • 0028265445 scopus 로고    scopus 로고
    • Salomone JA, Thomas RW, Althoff JR et al. An evaluation of the role of the ED in the management of migraine headaches. Am. J. Emerg. Med. 12, 134-137 (1994).
    • Salomone JA, Thomas RW, Althoff JR et al. An evaluation of the role of the ED in the management of migraine headaches. Am. J. Emerg. Med. 12, 134-137 (1994).
  • 28
    • 33444474876 scopus 로고    scopus 로고
    • Headache patients: Who does not come to the emergency department?
    • Lane PL, Nituica CM, Sorondo B. Headache patients: who does not come to the emergency department? Acad. Emer. Med. 10, 528 (2003).
    • (2003) Acad. Emer. Med , vol.10 , pp. 528
    • Lane, P.L.1    Nituica, C.M.2    Sorondo, B.3
  • 29
    • 0034083276 scopus 로고    scopus 로고
    • Patients with primary headache disorders in the emergency department
    • Blumenthal HJ, Weisz MA, Kelly KM. Patients with primary headache disorders in the emergency department. Head. Q. 11, 25-31 (2000).
    • (2000) Head. Q , vol.11 , pp. 25-31
    • Blumenthal, H.J.1    Weisz, M.A.2    Kelly, K.M.3
  • 30
    • 0031835817 scopus 로고    scopus 로고
    • The economic burden of migraine to society
    • Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 13, 667-676 (1998).
    • (1998) Pharmacoeconomics , vol.13 , pp. 667-676
    • Ferrari, M.D.1
  • 31
    • 0037345762 scopus 로고    scopus 로고
    • Migraine preventive medication reduces resource utilization
    • Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache 43, 171-178 (2003).
    • (2003) Headache , vol.43 , pp. 171-178
    • Silberstein, S.D.1    Winner, P.K.2    Chmiel, J.J.3
  • 32
    • 33444464557 scopus 로고    scopus 로고
    • MIDAS as a healthcare utilization predictor in tertiary care headache management
    • Freitag FG, Diamond S, Diamond ML, Urban GJ. MIDAS as a healthcare utilization predictor in tertiary care headache management. Neurology 56, A311-A312 (2001).
    • (2001) Neurology , vol.56
    • Freitag, F.G.1    Diamond, S.2    Diamond, M.L.3    Urban, G.J.4
  • 33
    • 33744496176 scopus 로고    scopus 로고
    • A multicentre, double-blind, randomised, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of migraine headache
    • Relja M, Poole AC, Schoenen J et al. A multicentre, double-blind, randomised, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of migraine headache. J. Neurol. 252(Suppl. 2), 62 (2005).
    • (2005) J. Neurol , vol.252 , Issue.SUPPL. 2 , pp. 62
    • Relja, M.1    Poole, A.C.2    Schoenen, J.3
  • 34
    • 0033917504 scopus 로고    scopus 로고
    • Botulinum toxin type A as a migraine preventive treatment
    • Silberstein SD, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 40, 445-450 (2000).
    • (2000) Headache , vol.40 , pp. 445-450
    • Silberstein, S.D.1    Mathew, N.2    Saper, J.3    Jenkins, S.4
  • 35
    • 24144474227 scopus 로고    scopus 로고
    • Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial
    • Silberstein SD, Stark SR, Lucas S, Christie S, DeGryse R, Turkel C. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc. 80, 1126-1137 (2005).
    • (2005) Mayo Clin. Proc , vol.80 , pp. 1126-1137
    • Silberstein, S.D.1    Stark, S.R.2    Lucas, S.3    Christie, S.4    DeGryse, R.5    Turkel, C.6
  • 36
    • 17244368592 scopus 로고    scopus 로고
    • Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial
    • Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45, 293-307 (2005).
    • (2005) Headache , vol.45 , pp. 293-307
    • Mathew, N.T.1    Frishberg, B.M.2    Gawel, M.3    Dimitrova, R.4    Gibson, J.5    Turkel, C.6
  • 37
    • 34248391281 scopus 로고    scopus 로고
    • Botulinum toxin type A in the treatment of chronic migraine without medication overuse
    • Freitag FG, Diamond S, Diamond ML, Urban GJ, Brooks KE. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Neurology 66, A224 (2006).
    • (2006) Neurology , vol.66
    • Freitag, F.G.1    Diamond, S.2    Diamond, M.L.3    Urban, G.J.4    Brooks, K.E.5
  • 38
    • 34248398351 scopus 로고    scopus 로고
    • Efficacy of prophylactic treatment with botulinum toxin type A in migraineurs with chronic daily headache overusing acute headache pain medication
    • Presented at:, Los Angeles, CA, USA, June 23
    • Saper JR, Brandes JL, Wrubel B, Dodick DW, DeGryse R, VanDenburgh AM. Efficacy of prophylactic treatment with botulinum toxin type A in migraineurs with chronic daily headache overusing acute headache pain medication. Presented at: 48th Annual Scientific Meeting of the American Headache Society. Los Angeles, CA, USA, June 23 (2006).
    • (2006) 48th Annual Scientific Meeting of the American Headache Society
    • Saper, J.R.1    Brandes, J.L.2    Wrubel, B.3    Dodick, D.W.4    DeGryse, R.5    VanDenburgh, A.M.6
  • 39
    • 17244371697 scopus 로고    scopus 로고
    • Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45, 315-324 (2005). • Well-designed clinical trials that ask important questions of a priori analysis methodology, of potential factors, which predict the outcome of a pharmacologic agent, are demonstrated by the trials of botulinum toxin type A in chronic headache. This article serves as an excellent example of the utility of this approach.
    • Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45, 315-324 (2005). • Well-designed clinical trials that ask important questions of a priori analysis methodology, of potential factors, which predict the outcome of a pharmacologic agent, are demonstrated by the trials of botulinum toxin type A in chronic headache. This article serves as an excellent example of the utility of this approach.
  • 40
    • 33750710500 scopus 로고    scopus 로고
    • Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 125, 286-295 (2006). •• Just as the occurrence of cutaneous allodynia may serve as an important marker for acute migraine treatment success and a potential factor in chronic migraine, understanding clinical correlates of the nature of pain may also have implications for predicting success with preventive therapies. The methodology still requires controlled clinical trials as well as examination in association with the use of other preventive medications.
    • Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 125, 286-295 (2006). •• Just as the occurrence of cutaneous allodynia may serve as an important marker for acute migraine treatment success and a potential factor in chronic migraine, understanding clinical correlates of the nature of pain may also have implications for predicting success with preventive therapies. The methodology still requires controlled clinical trials as well as examination in association with the use of other preventive medications.
  • 42
    • 33749123563 scopus 로고    scopus 로고
    • Botulinum toxin A in the treatment of migraine headache in children
    • Kabbouche MA, Hershey AD, Powers SW. Botulinum toxin A in the treatment of migraine headache in children. Headache 45, 776-79043 (2005).
    • (2005) Headache , vol.45 , pp. 776-79043
    • Kabbouche, M.A.1    Hershey, A.D.2    Powers, S.W.3
  • 43
    • 33746666618 scopus 로고    scopus 로고
    • Practical considerations for the treatment of elderly patients with migraine
    • Sarchielli P, Mancini ML, Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging 23, 461-489 (2006).
    • (2006) Drugs Aging , vol.23 , pp. 461-489
    • Sarchielli, P.1    Mancini, M.L.2    Calabresi, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.